Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned an average rating of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $22.11.

Several equities analysts recently commented on the company. Mizuho initiated coverage on Neumora Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock opened at $12.78 on Tuesday. The company’s 50-day moving average price is $11.77 and its 200-day moving average price is $11.31. Neumora Therapeutics has a 12-month low of $8.33 and a 12-month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, meeting the consensus estimate of ($0.37). Equities analysts forecast that Neumora Therapeutics will post -1.51 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Robert A. Lenz sold 30,788 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares of the company’s stock, valued at approximately $4,006,011.05. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Joshua Pinto sold 28,496 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total value of $331,408.48. Following the sale, the chief financial officer now owns 210,469 shares of the company’s stock, valued at $2,447,754.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,926 shares of company stock valued at $1,067,758. 26.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new stake in Neumora Therapeutics in the 1st quarter worth $10,354,000. Baker BROS. Advisors LP purchased a new stake in shares of Neumora Therapeutics during the first quarter worth about $8,715,000. Callan Capital LLC grew its stake in shares of Neumora Therapeutics by 222.6% in the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after purchasing an additional 456,207 shares during the last quarter. Artal Group S.A. increased its holdings in Neumora Therapeutics by 14.5% during the 1st quarter. Artal Group S.A. now owns 2,924,052 shares of the company’s stock valued at $40,206,000 after purchasing an additional 371,350 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Neumora Therapeutics by 474.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock valued at $2,316,000 after purchasing an additional 194,559 shares during the last quarter. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.